Vilon vs Crystagen — Peptide Comparison

Vilon vs Crystagen — Peptide Comparison Vilon vs Crystagen — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Vilon 5–10 mg Crystagen 1–100 mcg/kg Frequency Once daily Administration Subcutaneous injection Cycle Length 12+ weeks 8-12 weeks Onset Speed Gradual (3-4 weeks) Evidence Level Limited human trials Efficacy Immune System Revival Healthy Aging Digestive Support Immune Rejuvenation Cancer Defense Technical Data Molecular Formula C11H21N3O5 Molecular Weight 275.3 g/mol Half-Life Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic modifications to SIRT1/PARP gene expression; metabolized to constituent amino acids Bioavailability Absorbed via intestinal peptide transporters (PepT1) when administered orally (demonstrated in animal studies); rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short dipeptide structure CAS Number 45234-02-4 C14H21N3O8 359.3 g/mol Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure Not assigned (patented as immunogeroprotective peptide, US8057810B2) Protocols starting 200–500 mcg 5–10 day course Common Khavinson-style introductory protocol for the KE (Lys-Glu) immune bioregulator; courses repeated 2–3 times yearly [6]. Research use only — no approved product. standard 500 mcg 10–12 day course Typical full-course practice dose; cycle repeated every 3–6 months [6]. advanced Intramuscular delivery is also documented for the injectable KE bioregulator; same per-course dosing as subcutaneous [6]. 200-400 mcg 10-20 days per course, repeated every 4-6 months For the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6] Can also be given as an intramuscular injection at a similar dose, used in research practice. [6] 1-2 capsules (10 mg each) 1-2 times daily with meals 10-30 day course, repeated every 4-6 months The oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. [6] Applications Immune system restoration in aging individuals with declining thymic function Vilon is particularly well-suited for individuals focused on immune system restoration in aging individuals with declining thymic function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Adjunctive immunomodulatory support during cancer treatment protocols Vilon is particularly well-suited for individuals focused on adjunctive immunomodulatory support during cancer treatment protocols. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity Vilon is particularly well-suited for individuals focused on geroprotective therapy targeting sirt1/parp pathways for cellular longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Comprehensive Khavinson bioregulator protocols for anti-aging and immune support Vilon is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for anti-aging and immune support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Restoring thymic function and immune competence in aging individuals with immune senescence Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Comprehensive Khavinson bioregulator protocols for immune and anti-aging support Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Supporting immune function during and after illness recovery Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Injection site reaction Mild fatigue Mild headache Digestive changes Uncommon Flu-like symptoms Serious No documented serious adverse effects Minor digestive changes Research Status FDA Status Research compound Safety Overview Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature. Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk. Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity. Contraindications xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid) xPregnancy and breastfeeding — insufficient reproductive safety data xActive autoimmune disease in flare without medical supervision xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available. xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline) xActive autoimmune disease in flare without physician supervision Decision Guide Choose Vilon if... Immune system restoration in aging individuals with declining thymic function Adjunctive immunomodulatory support during cancer treatment protocols Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity Comprehensive Khavinson bioregulator protocols for anti-aging and immune support Choose Crystagen if... Restoring thymic function and immune competence in aging individuals with immune senescence Comprehensive Khavinson bioregulator protocols for immune and anti-aging support Supporting immune function during and after illness recovery Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence